22 June 2026 : Original article
[In Press] Four Years of Clinical Experience With COVID-19 Outcomes in Heart Transplant Recipients
Agnieszka KuczajDOI: 10.12659/AOT.952888
Ann Transplant In Press; DOI: 10.12659/AOT.952888
Available online: 2026-06-22, In Press, Corrected Proof
Publication in the "In-Press" formula aims at speeding up the public availability of the pending manuscript while waiting for the final publication. The assigned DOI number is active and citable. The availability of the article in the Medline, PubMed and PMC databases as well as Web of Science will be obtained after the final publication according to the journal schedule
Abstract
BACKGROUND
COVID-19 significantly impacted the outcomes of patients, particularly those with comorbidities, including solid organ transplant recipients. The aim of this study was to investigate the incidence and mortality of COVID-19, as well as to identify independent risk factors associated with COVID-19–related death in patients undergoing orthotopic heart transplantation (OHT).
MATERIAL AND METHODS
The study followed 556 heart transplant recipients at a high-volume transplant center in Poland from March 2020 to March 2024. Patients were classified as infected based on a positive result from reverse transcription-polymerase chain reaction (RT-PCR) tests or SARS-CoV-2 antigen rapid tests performed on nasopharyngeal swab samples.
RESULTS
In the analyzed cohort, 189 of 556 patients (33.99%; 40 women, 21.16%) were diagnosed with COVID-19 following OHT. In total, 15 patients (7.94%) experienced recurrent SARS-CoV-2 infections, with 1 patient being diagnosed 3 times. A total of 33 patients (5.94%) required hospitalization due to COVID-19. Among the entire study cohort, 75 patients (13.49%) died, with 18 of these deaths (24%) directly attributable to COVID-19. In the multivariable analysis, vaccination against COVID-19 was identified as a protective factor against death due to the virus (OR, 0.22; 95% CI, 0.07-0.68; P=0.009) while increasing age was associated with a higher risk of mortality (OR, 1.08; 95% CI, 1.02-1.14; P=0.008).
CONCLUSIONS
The lack of COVID-19 vaccination and advanced age significantly influenced the COVID-19–related mortality risk.
Keywords: COVID-19; Heart Transplantation; Immunosuppression Therapy; Mortality; SARS-CoV-2
In Press
Original article
iTRAQ- and MRM-Based Proteomics Identify Early Injury Biomarkers for Primary Dysfunction After Liver Transp...Ann Transplant In Press; DOI: 10.12659/AOT.952366
Case report
Tongue Carcinoma in Immunosuppressed Patients After Liver and Kidney Transplantation: A Case SeriesAnn Transplant In Press; DOI: 10.12659/AOT.951715
Original article
Prevalence and Risk Factors of Hepatic Steatosis in Kidney Transplant RecipientsAnn Transplant In Press; DOI: 10.12659/AOT.952251
Original article
The Anatomical Landscape of Living Donor Livers: A 101-Case Retrospective Single-Center Study in Indonesia ...Ann Transplant In Press; DOI: 10.12659/AOT.952031
Most Viewed Current Articles
24 Aug 2021 : Review article 20,504
Normothermic Machine Perfusion (NMP) of the Liver – Current Status and Future PerspectivesDOI :10.12659/AOT.931664
Ann Transplant 2021; 26:e931664
29 Dec 2021 : Original article 16,603
Efficacy and Safety of Tacrolimus-Based Maintenance Regimens in De Novo Kidney Transplant Recipients: A Sys...DOI :10.12659/AOT.933588
Ann Transplant 2021; 26:e933588
05 Apr 2022 : Original article 15,871
Impact of Statins on Hepatocellular Carcinoma Recurrence After Living-Donor Liver TransplantationDOI :10.12659/AOT.935604
Ann Transplant 2022; 27:e935604
22 Nov 2022 : Original article 15,778
Long-Term Effects of Everolimus-Facilitated Tacrolimus Reduction in Living-Donor Liver Transplant Recipient...DOI :10.12659/AOT.937988
Ann Transplant 2022; 27:e937988






